28821-18-3

Basic information

• Product Name: 7-(ethylamino)-4-methyl-2-benzopyrone
• Synonyms: 7-(ethylamino)-4-methyl-2-benzopyrone;7-(ethylamino)-4-methylcoumarin;7-(Ethylamino)-4-methyl-2H-1-benzopyran-2-one
• CAS NO: 28821-18-3
• Molecular Formula: C₁₂H₁₃NO₂
• Molecular Weight: 203.23712
• EINECS: 249-257-2
• Mol File: 28821-18-3.mol
• Article Data: 18

Chemical Properties

• Melting Point: 152.0 to 156.0 °C
• Boiling Point: 374.7°Cat760mmHg
• Flash Point: 180.4°C
• Appearance: /
• Density: 1.188g/cm³
• Vapor Pressure: 8.22E-06mmHg at 25°C
• Refractive Index: 1.602
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• CAS DataBase Reference: 7-(ethylamino)-4-methyl-2-benzopyrone(CAS DataBase Reference)
• NIST Chemistry Reference: 7-(ethylamino)-4-methyl-2-benzopyrone(28821-18-3)
• EPA Substance Registry System: 7-(ethylamino)-4-methyl-2-benzopyrone(28821-18-3)

Safety Data

• Hazardous Substances Data: 28821-18-3(Hazardous Substances Data)

Usage

General Description

7-(ethylamino)-4-methyl-2-benzopyrone, also known as ethyl apigenin, is a chemical compound with a molecular formula C15H13NO2. It is a synthetic derivative of apigenin, a natural flavonoid found in certain plants and herbs. Ethyl apigenin is known for its potential as an antioxidant and anti-inflammatory agent, and it has been studied for its possible therapeutic effects on various diseases, including cancer and neurodegenerative disorders. It has also been investigated for its potential as a sunscreen ingredient due to its ability to absorb UV radiation. Additionally, ethyl apigenin has shown antimicrobial properties against certain strains of bacteria and fungi. Due to its various potential health benefits, this compound is the subject of ongoing research in the fields of medicine and skincare.

InChI:InChI=1/C12H13NO2/c1-3-13-9-4-5-10-8(2)6-12(14)15-11(10)7-9/h4-7,13H,3H2,1-2H3

Upstream product

• 91-44-1 7-diethylamino-4-methylcoumarin 
• 621-31-8 3-(ethylamino)phenol 
• 141-97-9 ethyl acetoacetate 
• 1346523-56-5 7-[ethyl-(4-methanesulfonylphenyl)amino]-4-methylcoumarin 
• 26093-31-2 7-amino-4-methylcoumarin. 
• 58632-48-7 (4-methyl-2-oxo-2H-1-benzopyran-7-yl)carbamic acid ethyl ester 
• 101973-09-5 7-[N-(p-toluenesulfonyl)amino]-4-methylcoumarin 
• 591-27-5 m-Hydroxyaniline 
• 7159-96-8 ethyl N-(3-hydroxyphenyl)carbamate 
• 75-03-6 ethyl iodide 

Downstream Products

• 1264299-02-6 C₂₀H₂₀BrNO₃ 
• 1264299-01-5 C₁₉H₁₈BrNO₂ 
• 1346523-59-8 4-{[ethyl-(4-methylcoumarin-7-yl)amino]methyl}benzoic acid methyl ester 
• 1346523-61-2 4-{[ethyl-(4-methylcoumarin-7-yl)amino]methyl}benzoic acid 
• 1441046-64-5 4-(7-(ethylamino)-4-methyl-2-oxo-2H-chromen-3-yl)-benzaldehyde 
• 1017606-29-9 C₁₉H₁₆INO₃ 

Relevant articles and documents

Discovery of Potent Coumarin-Based Kinetic Stabilizers of Amyloidogenic Immunoglobulin Light Chains Using Structure-Based Design

In immunoglobulin light-chain (LC) amyloidosis, transient unfolding or unfolding and proteolysis enable aggregation of LC proteins, causing potentially fatal organ damage. A drug that kinetically stabilizes LCs could suppress aggregation; however, LC sequences are variable and have no natural ligands, hindering drug development efforts. We previously identified high-throughput screening hits that bind to a site at the interface between the two variable domains of the LC homodimer. We hypothesized that extending the stabilizers beyond this initially characterized binding site would improve affinity. Here, using protease sensitivity assays, we identified stabilizers that can be divided into four substructures. Some stabilizers exhibit nanomolar EC50 values, a 3000-fold enhancement over the screening hits. Crystal structures reveal a key π-πstacking interaction with a conserved tyrosine residue that was not utilized by the screening hits. These data provide a foundation for developing LC stabilizers with improved binding selectivity and enhanced physicochemical properties.

BENZOPYRANE AND IMIDAZOLE DERIVATIVES USEFUL FOR THE STABILIZATION OF AMYLOIDOGENIC IMMUNOGLOBULIN LIGHT CHAINS

In immunoglobulin light chain amyloidosis (AL), the unique antibody light chain (LC) protein that is secreted by monoclonal plasma cells in each patient misfolds and/or aggregates, a process leading to organ degeneration. For treating AL patients, such as those with substantial cardiac involvement who have difficulty tolerating existing chemotherapy regimens, provided herein are small molecule compounds of Formula Ia, Formula Ib, and Formula II that are kinetic stabilizers of the native dimeric structure of full-length LCs, which compounds can slow or stop the amyloidogenicity cascade at its origin.

7-substituted amino-4-methylcoumarin derivative, as well as preparation method and medical application thereof

The invention belongs to the field of medicinal chemistry, and relates to a 7-substituted amino-4-methylcoumarin derivative, as well as a preparation method and application of the 7-substituted amino-4-methylcoumarin derivative as a therapeutic agent in the medical aspect, especially as an ALDH1A1 inhibitor in the aspects of reducing blood glucose and the like.